Health Care Select Sector SPDR Fund (XLV)
| Assets | $36.90B |
| Expense Ratio | 0.08% |
| PE Ratio | 22.27 |
| Shares Out | 252.67M |
| Dividend (ttm) | $2.44 |
| Dividend Yield | 1.67% |
| Ex-Dividend Date | Sep 22, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | 37.23% |
| Volume | 6,458,857 |
| Open | 146.09 |
| Previous Close | 146.03 |
| Day's Range | 145.22 - 146.45 |
| 52-Week Low | 127.35 |
| 52-Week High | 150.95 |
| Beta | 0.64 |
| Holdings | 63 |
| Inception Date | Dec 16, 1998 |
About XLV
Fund Home PageThe Health Care Select Sector SPDR Fund (XLV) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund tracks health care stocks from within the S&P 500 Index, weighted by market cap. XLV was launched on Dec 16, 1998 and is issued by State Street.
Top 10 Holdings
56.65% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 12.37% |
| Johnson & Johnson | JNJ | 8.65% |
| AbbVie Inc. | ABBV | 7.59% |
| UnitedHealth Group Incorporated | UNH | 6.19% |
| Abbott Laboratories | ABT | 4.16% |
| Merck & Co., Inc. | MRK | 4.12% |
| Thermo Fisher Scientific Inc. | TMO | 4.08% |
| Intuitive Surgical, Inc. | ISRG | 3.69% |
| Amgen Inc. | AMGN | 2.96% |
| Gilead Sciences, Inc. | GILD | 2.83% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 22, 2025 | $0.62487 | Sep 24, 2025 |
| Jun 23, 2025 | $0.63038 | Jun 25, 2025 |
| Mar 24, 2025 | $0.56454 | Mar 26, 2025 |
| Dec 23, 2024 | $0.62166 | Dec 26, 2024 |
| Sep 23, 2024 | $0.57723 | Sep 25, 2024 |
| Jun 24, 2024 | $0.57253 | Jun 26, 2024 |
Performance
XLV had a total return of 0.26% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.41%.
News
The Utterly Tranquil Feeling Of Watching Your Passive Income Grow
Dividend growth investing offers reliable, passive income and personal tranquility, more so than non-dividend strategies and rental property investing. Current market valuations, especially in Big Tec...
October's 5 Dividend Growth Stocks With Yields Up To 8.33%
Every month, we screen for high-yield dividend yields, but those that also deliver relatively consistent growth with regular dividend increases. The parameters of the screening also include dividend s...
XLV: Lower Interest Rates And A Positive Growth Outlook Will Pave The Way
The Fed has begun to reduce interest rates in the U.S. This decision will incentivize the deployment of funding in the healthcare industry. The top holdings of XLV are profitable firms, with a median ...
AI train is moving to non-tech sectors like financials and health care: BofA's Savita Subramanian
Savita Subramanian, Bank of America Securities head of equity and quantitative strategy, joins 'The Exchange' to discuss the current market catalysts and concerns.
New Prescription for Gains: Behind Q4 Healthcare Lead
It's early days, but the fourth quarter has brought a change in market leadership at the sector level. Healthcare, one of the year's big laggards, is now the best performing S&P 500 sector so far in O...
What AMD's OpenAI deal means for Nvidia, healthcare stocks see major gains in 2025
Morning Brief: Market Sunrise anchor Ramzan Karmali examines the biggest market news and stories for October 7, 2025. CFRA research analyst Angelo Zino comes on the program to talk more about AMD's AI...
Confluence of factors are bringing investment into biotech sector, says StemPoint's Michelle Ross
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss Ross' thoughts on the recent news in the biotech space, what the CIO expects to continue and much more.
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
5 Dividend Stocks I Can't Wait To Buy In October (Plus Macro Update)
The US stock market is highly concentrated, with technology and tech-related stocks now comprising about 55% of total market cap. This concentration justifies higher valuation multiples for SPY, as te...
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Every pharma company I cover has U.S. production so tariffs are more bark than bite: BMO's Seigerman
Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'Closing Bell' to discuss President Trump's latest tariff announcement on pharmaceutical companies, where execution needs to happ...
2 Call Writing Funds Providing Monthly Distributions For Passive Income
Call writing closed-end funds can offer attractive monthly distributions, along with the opportunity to trade at discounts to their historical net asset values. That discount can create an opportunity...
XLV: Market Overreaction Could Drive Double Digit Shareholder Yield
Healthcare sector trades at a historic discount due to patent expirations, managed care uncertainty, and drug pricing proposals, but pessimism is overdone. Key catalysts include potential M&A activity...
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
XLV Vs. IHE: Will Pharmaceuticals Outperform Healthcare?
Healthcare is a defensive sector with strong long-term growth drivers like demographics, innovation, and rising healthcare spending. I rate XLV a buy due to its diversified exposure across healthcare ...
Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.
They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.
Healthcare industry can handle and absorb tariffs, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Power Lunch' to discuss what tariffs mean for the pharma industry, what could be a blockbuster for Eli Lilly and much more.
Health care sector is resilient, 'won't stay down forever', says Evan May Wealth's Brooke Evans
Brooke May, Evans May Wealth managing partner, joins 'Closing Bell Overtime' to talk what sectors she is keeping an eye on in this market.
Healthcare Stocks Are Trading at Their Biggest Discount in 30 Years. Why a Turnaround May Have Already Started.
For investors worried about elevated market valuations, they may be just what the doctor ordered.
Gill: We're at a real inflection point for healthcare
Lisa Gill, JP Morgan healthcare analyst, on “Worldwide Exchange,” says healthcare is at an inflection point, with UnitedHealth poised for long-term gains as big investors bet on a turnaround.
Mizuho's Jared Holz on how to play the underperforming health care sector
Jared Holz, Mizuho Securities healthcare sector strategist, joins 'The Exchange' to discuss Insmed's lung drug being greenlit by the FDA and his read on the healthcare sector.
Final Trades: Netflix, Wynn Resorts, Buckle and the XLV
The Investment Committee give you their top stocks to watch for the second half.
US FDA announces new program to boost domestic drug manufacturing
The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain, by facilitating construction of manufacturing sites in the United Stat...
Key ETF Asset Class Performance
The market ended the month of July on a down note, but the S&P 500 still ended the month with a gain of 2.3%. While domestic equities posted small gains in July, there was quite a bit of disparity amo...
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Managed care needs to improve to improve health care sector, says Mizuho's Jared Holz
Jared Holz, Mizuho health care sector strategist, joins 'The Exchange' to discuss the pain in the health care sector and if there are any opportunity plays within.
Trump's deadline looms for Big Pharma companies facing new tariffs
'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.
XLV: Life Expectancy, Patents, And A Positive Outlook Will Pave The Way
The life expectancy has increased in the U.S. and worldwide, contributing to healthcare companies retaining their patients for longer periods. Investors pay low fees to hold XLV, since the expense rat...
Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff
A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.
Measuring Options Activity in MRK & XLV: Healthcare Levels to Watch
Rick Ducat turns to the healthcare sector on today's options analysis. He starts with the SPDR Health Care ETF (XLV), noting the recent breakdown of a head and shoulders pattern and potential for both...
XLV: The S&P 500's Most Discounted Sector? Uncover The Hidden Risk
The healthcare segment, and therefore XLV, is, in terms of relative valuations, the most attractive earning-driven sector. The strong dissonance between earnings expectations and price decline highlig...
2 Healthcare Picks For Distributions And Attractive Valuations
Healthcare CEFs are under pressure from regulatory shifts, but sector defensiveness and discounted valuations can create long-term opportunities. Within the CEF structure, we also have the added benef...
I've never seen a setup this negative for health care job growth, says Bancreek's Pachman
CNBC's “Power Lunch” is joined by Eric Pachman, chief analytics officer at Bancreek Capital Advisors, to discuss the U.S. labor market, whether health care jobs are in jeopardy and more.
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
Buy America, says John Hancock's Matthew Miskin
Matthew Miskin, John Hancock Investment Management, joins 'The Exchange' to discuss markets, small and mid-caps and the industrial sector.
How pet medicine stocks could cushion your healthcare investments from Trump changes
Moderna shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investmen...
The HealthCare Sector: A Look At Sector Earnings Trends
Looking at Q1 '25 earnings trends, the healthcare sector reported a solid quarter, even with UnitedHealth's issues. Q2 and Q3 '25 are showing lower or negative revisions, and lower levels of absolute ...
3 Deep-Value Blue Chips: The Fat Pitch I Couldn't Resist
The worst-case scenario of big global tariffs and a severe recession is now off the table, lowering risk and supporting a new bull market. UnitedHealth offers a Buffett-style deep value opportunity af...
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
Final Trade: BABA, JPM, XLV, JBLU
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
XLV: Trump's Drug Price Talk Revives Old Headlines, Not New Risks
The current market environment is the best I've seen in 30+ years, driven by risk management, blending technical and quantitative analysis, and ignoring most headlines. XLV, the Healthcare Sector SPDR...
StemPoint's Michelle Ross breaks down navigating the pharmaceutical sector volatility
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss health care's weak week and how to navigate pharma volatility.
Defensive Sectors Continue To Lead U.S. Stock Market This Year
President Trump announced a US-UK trade deal yesterday, which may be an early sign of a thaw in the global trade war. Although the broad US stock market has rebounded sharply in recent weeks, the reco...
Final Trade: SBUX, META, XLV and BABA
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
XLV Vs. VHT: I Prefer XLV For Its Better Downturn Resilience
The Healthcare Sector, represented by XLV and VHT ETFs, offers a defensive investment option amid current market volatility and potential recession risks. Between these two funds, I prefer XLV even be...